Leah Lawrence

Biomarker identification could allow for precision therapy in women with this subtype.

Lack of initial response to imatinib might indicate need to switch to dasatinib.

Immune checkpoint inhibition may even benefit some patients with MMR-proficient tumors.

Treatment effects of pathologic CR, DFS, ORR, and PFS were not strongly correlated with treatment effects on overall survival.

Use of PCI after thoracic radiation did not improve survival.

Recommendations issued apply to patients and those providing patient care.

More research is needed to define criteria for stopping therapy.

Nonsignificant variation of acquired resistance occurred by drug type.

Although papillary thyroid carcinoma subtypes are often lumped together, mortality risk varied greatly across subtypes.

The patient recovered from pneumonia and stable disease was observed.